Proactive Investors - Run By Investors For Investors

Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading

Geremy Thomas, founder and chief executive officer of the medicinal cannabis and wellness cannabidiol (CBD) group said: "Sativa is delivering real revenues in a new and exciting sector"
Cannabis oils
The NEX-listed firm also said all resolutions were duly passed at today’s AGM including its proposed name change to Sativa Group PLC

Sativa Investments PLC (LON:SATI) has said its current financial year has begun well, with 2019 first quarter revenues exceeding total revenues in the group’s first year of trading.

In a brief trading statement to coincide with Wednesday’s annual general meeting, Geremy Thomas, founder and chief executive officer of the medicinal cannabis and wellness cannabidiol (CBD) group said: "Sativa is delivering real revenues in a new and exciting sector.  Key value drivers include manufacturing capability, testing, brands and distribution."

READ: Sativa Investments signs supply deal with Swiss cannabis oil producer Alponics

The Company also noted that, since the year-end, it has announced two overseas CBD oil take-off agreements, appointed RSM as auditor, appointed a Director of Regulatory Affairs and also a retail professional to oversee the roll-out of the Goodbody wellness centres, the first of which opens in Bath on 28 June 2019. 

In April 2019, the Company entered in to into a three-year research agreement with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases.

The NEX-listed firm also said all resolutions were duly passed at today’s AGM including its proposed name change to Sativa Group PLC, which, now ratified by shareholders, will be completed within days.

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use